TARRYTOWN, N.Y.--(BUSINESS WIRE)--PGI Drug Discovery LLC (PsychoGenics) announced that it has expanded its CNS drug discovery partnership with Roche and extended the agreement for another five years.
In April 2008, PsychoGenics and Roche entered into a drug discovery and development agreement to combine their complementary strengths and expertise to identify a new generation of treatments for neuropsychiatric disorders. The teams utilize the phenotypic approach in a high throughput manner with SmartCube® to drive chemistry optimization efforts.
Help employers find you! Check out all the jobs and post your resume.
